A Multi-Center, Open-Label, Randomized, Active-Control, Parallel-Group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug Naive Type 2 Diabetes Mellitus Patients.

Trial Profile

A Multi-Center, Open-Label, Randomized, Active-Control, Parallel-Group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug Naive Type 2 Diabetes Mellitus Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Acarbose; Nateglinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ENERGY-1
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jul 2012 Results published in Current Medical Research and Opinion.
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top